Praxis Precision Medicines, Inc.
PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depressiā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$324.24
Price-2.28%
-$7.57
1Y
Price
Market Cap
$6.855b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR+49.8%
3y CAGR+37.4%
5y CAGREarnings
-$326.533m
-7.7%
1y CAGR-40.6%
3y CAGR-19.9%
5y CAGREPS
-$13.37
+0.8%
1y CAGR+4.7%
3y CAGR+21.8%
5y CAGRBook Value
$1.410b
$1.460b
Assets$50.241m
Liabilities$1.435m
DebtDebt to Assets
0.1%
-
Debt to EBITDAFree Cash Flow
-$282.905m
-13.6%
1y CAGR-40.4%
3y CAGR-20.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company